FMO5 and Parkinson disease: DM is a noncompetitive N-methyl-d aspartate (NMDA) receptor agonist that has been shown to have both anti-inflammatory [31] and neuroprotective properties in models of Parkinson's disease [31], [32], [33], independent of the NMDA receptor and through inhibition of microglial NADPH oxidase [35], [36].